These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 33068176)

  • 1. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative bioinformatics analysis reveals miR-494 and its target genes as predictive biomarkers of trastuzumab-resistant breast cancer.
    Hermawan A; Putri H
    J Egypt Natl Canc Inst; 2020 Apr; 32(1):16. PubMed ID: 32372307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.
    Sun C; Yang F; Zhang Y; Chu J; Wang J; Wang Y; Zhang Y; Li J; Li Y; Fan R; Li W; Huang X; Wu H; Fu Z; Jiang Z; Yin Y
    Cell Physiol Biochem; 2018; 49(2):419-431. PubMed ID: 30153663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
    Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
    Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
    Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
    Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.
    Du F; Yuan P; Zhao ZT; Yang Z; Wang T; Zhao JD; Luo Y; Ma F; Wang JY; Fan Y; Cai RG; Zhang P; Li Q; Song YM; Xu BH
    Sci Rep; 2016 Sep; 6():33825. PubMed ID: 27650797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
    Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
    Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
    Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Badr M; Said H; Louka ML; Elghazaly HA; Gaballah A; Atef Abd El Mageed M
    J Cell Biochem; 2019 Mar; 120(3):3459-3466. PubMed ID: 30246355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of serum exosomal miR-148a as a novel prognostic biomarker for breast cancer.
    Li D; Wang J; Ma LJ; Yang HB; Jing JF; Jia MM; Zhang XJ; Guo F; Gao JN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7303-7309. PubMed ID: 32706068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
    Zhang H; Zou X; Wu L; Zhang S; Wang T; Liu P; Zhu W; Zhu J
    Cancer Med; 2020 Feb; 9(3):1230-1241. PubMed ID: 31856390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
    Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
    Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Papadaki C; Stratigos M; Markakis G; Spiliotaki M; Mastrostamatis G; Nikolaou C; Mavroudis D; Agelaki S
    Breast Cancer Res; 2018 Jul; 20(1):72. PubMed ID: 29996899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
    Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
    [No Abstract]   [Full Text] [Related]  

  • 18. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
    Huang X; Yuan T; Liang M; Du M; Xia S; Dittmar R; Wang D; See W; Costello BA; Quevedo F; Tan W; Nandy D; Bevan GH; Longenbach S; Sun Z; Lu Y; Wang T; Thibodeau SN; Boardman L; Kohli M; Wang L
    Eur Urol; 2015 Jan; 67(1):33-41. PubMed ID: 25129854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
    Shao B; Wang X; Zhang L; Li D; Liu X; Song G; Cao H; Zhu J; Li H
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819828709. PubMed ID: 30786836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.